Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients
about
Different strains of Theiler's murine encephalomyelitis virus antagonize different sites in the type I interferon pathwayBiomarkers of therapeutic response in multiple sclerosis: current statusEBI2 is a negative regulator of type I interferons in plasmacytoid and myeloid dendritic cellsRelationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patientsInterferon-beta induces distinct gene expression response patterns in human monocytes versus T cellsFeasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosisThe orally available, synthetic ether lipid edelfosine inhibits T cell proliferation and induces a type I interferon responseReassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosisExcessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosisDissecting the heterogeneity of skin gene expression patterns in systemic sclerosisCombination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study.Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study.Assessing the human immune system through blood transcriptomics.Search for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosis.Molecular mechanism underlying the impact of vitamin D on disease activity of MS.Gene expression profiles in human peripheral blood mononuclear cells as biomarkers for nutritional in vitro and in vivo investigationsBaseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients.Baseline gene expression signatures in monocytes from multiple sclerosis patients treated with interferon-betaInterleukin 17F level and interferon β response in patients with multiple sclerosis.A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.Interferons in autoimmune and inflammatory diseases: regulation and roles.Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translationTranscriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis.Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis.Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ.Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance.Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseasesMeta-Analysis of Differential Connectivity in Gene Co-Expression Networks in Multiple Sclerosis.Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis.Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach.Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon.IFN-beta pharmacogenomics in multiple sclerosis.Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance.Type I interferon in organ-targeted autoimmune and inflammatory diseases.Determinants of interferon β efficacy in patients with multiple sclerosis.Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy.Pharmacogenomics and multiple sclerosis: moving toward individualized medicine.The genetics of multiple sclerosis: an up-to-date review.Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies.Genomics and proteomics: Applications in autoimmune diseases.
P2860
Q24611933-16C2F072-3A3A-4593-8482-AC493E4301D7Q27012726-40081EE8-0417-4D67-9131-7D76FB41E0E4Q27339798-B9BA46D8-56D8-441A-A074-9E08E38C7248Q28290930-8CC47C5B-65EB-4918-986B-AC13E382BD92Q28486504-5077DDB3-A8A4-4AA4-8F4B-00F911F633A2Q28535303-A731C7C1-A17E-43CD-B330-317E1DD0CCD5Q28541466-6B464A8D-24B8-4790-8482-9366E4F95ED8Q28740839-3DBD1B19-B98F-45F0-A346-609B3DE1D745Q28744592-918E9CF9-52F5-4367-95C3-154CD978EA12Q30845649-3CC0B7A3-97C1-4494-8D20-872540C1251AQ33393257-0377B6F1-6A92-43F0-A5DE-E5265D07963CQ33510256-FE9A64DD-723C-432B-AFC0-8D2A25F51A13Q33629522-F9A5DDB5-635E-4F35-97C9-217D785DFDE7Q34008878-BDA4840B-1845-4CED-9C43-CC019E7FB934Q34268651-BE19ACB1-96FA-474A-9C9A-B27946D9A57AQ34338696-448EA113-9C28-4DFD-8374-C84CBFF81CCBQ34513928-DAADBB39-0714-4428-A589-DF9905EB5E9BQ34700070-B70C6F57-2EA1-468C-B61A-2143DC1C945DQ34915610-9B696A22-00A8-48FC-91C2-918F29E3BD05Q35568496-EFDF8F32-5565-41F3-8FDF-E6F724F73607Q35603598-808CB68C-A987-4F1E-9479-112BD753B584Q35799841-04A5B6D5-6349-4CF1-B89E-CCCF17AA8AA8Q35847422-701AC8B3-FC87-447F-B36E-B240BED7C01FQ35848490-A31992DE-EE38-40F9-86B4-FA6AAE649CD3Q36247683-CA002150-0F58-4264-B038-621A94C771E7Q36298955-4A9298F6-8E9D-488B-B8F6-01E8465CDAC6Q36588160-D1D90C93-7787-419F-AE4B-6425DC09EABCQ37050779-04CBD547-DA3B-4941-85BB-0B6982DE38F5Q37221728-7EB49C8A-ABAA-4DD5-96B5-D03096CA5DD1Q37356528-8691FAC6-E7D6-486E-B141-74C8D8D7C81EQ37378782-B8FE6D81-349F-44A4-AFB7-C2C685EC2A92Q37780222-42E08625-4C20-4AF0-B9AF-BCDC7BE9CAFEQ37808291-33D46202-08D8-405B-957E-9351BFD883D6Q37838003-8C9B2F4B-A9B1-4F73-81BE-7BB1B1706478Q37848651-16F1277D-83DA-461C-9EB1-E1F779995F28Q37859376-1E3A1A70-60D8-4458-AB0C-6BCB9D022EACQ37893991-828CB9B4-DAB2-4764-9921-9C41AC2BCFB9Q38020959-1FCFF991-BDA1-4EB2-98DF-BAC8291E926FQ38050313-25FB0A7A-B80C-46BE-81AE-7DF3E99380A9Q38066181-2FC80A00-8155-4511-9A61-E503F632995F
P2860
Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients
description
2008 nî lūn-bûn
@nan
2008 թուականին հրատարակուած գիտական յօդուած
@hyw
2008 թվականին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Pharmacogenomics of interferon ...... l differences between patients
@ast
Pharmacogenomics of interferon ...... l differences between patients
@en
Pharmacogenomics of interferon ...... l differences between patients
@en-gb
Pharmacogenomics of interferon ...... l differences between patients
@nl
type
label
Pharmacogenomics of interferon ...... l differences between patients
@ast
Pharmacogenomics of interferon ...... l differences between patients
@en
Pharmacogenomics of interferon ...... l differences between patients
@en-gb
Pharmacogenomics of interferon ...... l differences between patients
@nl
altLabel
Pharmacogenomics of Interferon ...... l Differences between Patients
@en
prefLabel
Pharmacogenomics of interferon ...... l differences between patients
@ast
Pharmacogenomics of interferon ...... l differences between patients
@en
Pharmacogenomics of interferon ...... l differences between patients
@en-gb
Pharmacogenomics of interferon ...... l differences between patients
@nl
P2093
P2860
P921
P3181
P1433
P1476
Pharmacogenomics of interferon ...... l differences between patients
@en
P2093
Chris H Polman
Cornelis L Verweij
Joep Killestein
Josefien M C Baggen
Laura F van der Voort
Lisa G M van Baarsen
Marianne Tijssen
Saskia Vosslamber
Tineke C T M van der Pouw Kraan
P2860
P3181
P356
10.1371/JOURNAL.PONE.0001927
P407
P577
2008-01-01T00:00:00Z